Active Ingredient History
Naturally occurring xenon (54Xe) consists of seven stable isotopes and two very long-lived isotopes. Double electron capture has been observed in 124Xe and double beta decay in 136Xe, which are among the longest measured half-lives of all nuclides. The isotopes 126Xe and 134Xe are also predicted to undergo double beta decay, but this has never been observed in these isotopes, so they are considered to be stable. Beyond these stable forms, 32 artificial unstable isotopes and various isomers have been studied, the longest-lived of which is 127Xe with a half-life of 36.345 days. All other isotopes have half-lives less than 12 days, most less than 20 hours. The shortest-lived isotope, 108Xe, has a half-life of 58 μs, and is the heaviest known nuclide with equal numbers of protons and neutrons. Of known isomers, the longest-lived is 131mXe with a half-life of 11.934 days. 129Xe is produced by beta decay of 129I ; 131mXe, 133Xe, 133mXe, and 135Xe are some of the fission products of both 235U and 239Pu, so are used as indicators of nuclear explosions. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Lung Diseases (approved 2022)
Allergy and Immunology (Early Phase 1)
Alveolitis, Extrinsic Allergic (Phase 2)
Alzheimer Disease (Early Phase 1)
Anemia (Phase 2)
Anesthesia (Early Phase 1)
Anxiety (Early Phase 1)
Asbestosis (Early Phase 1)
Asthma (Phase 2)
Bipolar Disorder (Early Phase 1)
Brain Ischemia (Phase 2)
Bronchiectasis (Early Phase 1)
Bronchiolitis Obliterans (Phase 1/Phase 2)
Bronchopulmonary Dysplasia (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Cerebral Arteries (Phase 2)
Cerebral Infarction (Phase 2)
Common Cold (Early Phase 1)
Connective Tissue Diseases (Phase 2)
COVID-19 (Phase 2)
Cystic Fibrosis (Phase 4)
Depressive Disorder, Major (Early Phase 1)
Emphysema (Early Phase 1)
Familial Primary Pulmonary Hypertension (Phase 2)
Fibrosis (Phase 2)
Healthy Volunteers (Phase 1)
Heart Diseases (Phase 2)
Heart Failure (Phase 2)
Hypertension, Pulmonary (Phase 2)
Idiopathic Pulmonary Fibrosis (Phase 2)
Infections (Phase 1)
Ischemic Stroke (Phase 3)
Liver (Phase 4)
Lung (Early Phase 1)
Lung Diseases (Phase 4)
Lung Diseases, Interstitial (Phase 2)
Lung Neoplasms (Early Phase 1)
Lung Transplantation (Phase 2)
Mesothelioma (Early Phase 1)
Obesity (Phase 2)
Panic Disorder (Phase 2/Phase 3)
Parkinson Disease (Phase 1)
Polycythemia (Phase 2)
Pulmonary Arterial Hypertension (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 2/Phase 3)
Pulmonary Embolism (Phase 2)
Pulmonary Fibrosis (Early Phase 1)
Pulmonary Surgical Procedures (Phase 3)
Radiation Injuries (Phase 1)
Respiratory Tract Infections (Early Phase 1)
Sleep Apnea, Obstructive (Phase 4)
Stress Disorders, Post-Traumatic (Phase 2/Phase 3)
Stress, Psychological (Early Phase 1)
Subarachnoid Hemorrhage (Phase 2)
Vaping (Phase 1/Phase 2)
Xenon (Early Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
